Neurofilament Light Chain (NF-L)

I'll now create a professional scientific article on NEFL based on the provided publication contexts.

Overview

NEFL (neurofilament light chain, also abbreviated as NfL) is a cytoplasmic protein and a major structural component of neuronal intermediate filaments. As one of three neurofilament proteins (along with medium and heavy chains), NEFL is essential for maintaining axonal cytoskeletal integrity and normal neuronal function. When neurons undergo damage or degeneration, NEFL is released into the cerebrospinal fluid and subsequently into the bloodstream, where it can be quantified as a sensitive biomarker of neuroaxonal injury. This property has established NEFL as one of the most clinically relevant and increasingly implemented biomarkers in neurology, reflecting the degree of neuronal damage across multiple disease contexts.

NEFL functions as both a critical structural protein and as a disease-agnostic biomarker of neurodegeneration. Because neurofilament light chain levels in serum and cerebrospinal fluid correlate with the extent of neuroaxonal damage, measuring NEFL has become a powerful diagnostic, prognostic, and therapeutic response-monitoring tool in clinical neuroscience. Unlike disease-specific biomarkers, NEFL is applicable across numerous conditions—including neurodegenerative diseases, inflammatory neurological disorders, infectious diseases, and neuromuscular conditions—making it exceptionally valuable for assessing neurological disease activity and progression.

Recent Publications Summary

Recent studies continued to evaluate neurofilament light chain (NfL) as a circulating marker of axonal injury and disease activity across diverse neurologic disorders. In GM2 gangliosidoses, NfL was measured in participants enrolled in a phase 2b multinational study of levacetylleucine and its open-label extension, where NfL declined after 6 weeks of treatment and rebounded during washout; changes in NfL also correlated with clinically meaningful changes on the primary outcome measures, supporting its potential as a surrogate outcome biomarker in this ultra-rare neurodegenerative disease 42467089Jul. In amyotrophic lateral sclerosis, serum and CSF NfL were strongly associated with clinical features, disease progression, and survival in the METABALS cohort, and outperformed inflammatory mediators, CNS barrier markers, kynurenine pathway metabolites, and untargeted metabolomic profiles for prognostic value 42207242May.

Several studies examined NfL alongside other biomarkers in neuroimmunologic and neurodegenerative conditions. In multiple sclerosis, NfL was compared with glial fibrillary acidic protein (GFAP) and emerging CSF/serum candidates as part of efforts to identify biomarkers reflecting disease activity, severity, and pathophysiology 42024828Apr. In fingolimod-treated multiple sclerosis, serum NfL was assessed longitudinally together with serum GFAP to predict progression independent of relapse activity (PIRA) and relapse activity, with the study framing sNfL as a marker of treatment response or insufficient disease-modifying therapy effect 41237262Nov. In myasthenia gravis, however, plasma NfL did not differ from healthy controls, did not correlate with MG severity scales, and was not associated with crisis history or treatment exposure, arguing against its utility as a disease biomarker in that setting 42412876Jul.

NfL was also investigated in studies focused on differential diagnosis and comorbidity. In prion diseases, plasma NfL was measured alongside Alzheimer disease plasma biomarkers, including p-tau217, p-tau181, Aβ42/40, BD-tau, and GFAP, to assess whether these markers could distinguish prion disease from sporadic Alzheimer disease 42441927Jul. In temporal lobe epilepsy with comorbid depression, plasma NfL was compared with GFAP and phosphorylated tau species across patients with epilepsy, epilepsy plus depression, and healthy controls, with the study designed to test associations with clinical characteristics and depressive symptoms 42189430May. In a population-based cognitive aging study, higher plasma NfL was associated with increased cognitive impairment risk and was linked in mediation analyses to vitamin B12/Folate-related pathways, including associations with homocysteine, hemoglobin, and other Alzheimer biomarkers such as p-tau181, p-tau217, and GFAP 41980534Apr.

What Changes, What Holds

1. NfL is strengthening as a treatment-responsive surrogate in some neurodegenerative diseases, but its prognostic value remains disease-dependent
REINFORCES The new GM2 gangliosidosis and ALS data extend the established view of NfL as a circulating marker of axonal injury and disease activity, and they suggest it can track meaningful change over time in at least some settings 42467089Jul42207242May. At the same time, the ALS findings sharpen the baseline claim that NfL is broadly useful but not interchangeable with every other biomarker: it outperformed several inflammatory and metabolomic candidates for prognosis, yet that does not make it universally superior across disorders.

2. NfL is not a reliable biomarker for every neuroimmunologic disorder, and its value may be context-specific
REINFORCES The multiple sclerosis studies fit the baseline’s disease-agnostic framing while refining how NfL is used alongside GFAP and other candidates, especially for treatment response and progression risk 42024828Apr41237262Nov. By contrast, the negative myasthenia gravis study argues against assuming that elevated neuronal injury markers will map onto clinical severity in all immune-mediated diseases 42412876Jul. That weakens any overgeneralized use of NfL, but it does not overturn its established role where axonal injury is central.

3. NfL is also being used to separate overlapping neurologic syndromes and to link cognitive risk with broader metabolic pathways
NEW DIRECTION These studies move beyond the Overview’s core claim that NfL reflects neuroaxonal injury by showing new diagnostic and associative uses in prion disease, epilepsy with depression, and population cognitive aging 42441927Jul42189430May41980534Apr. The baseline does not specifically cover differential diagnosis against Alzheimer biomarkers or mediation through vitamin B12/folate-related pathways, so this is an added application rather than a contradiction. What remains unsettled is whether these associations are specific enough to guide practice or mainly reflect nonspecific injury burden.